

LncRNA AB073614 promotes tumor migration and invasion by repressing CDKN1A in non-small cell lung cancer

W.-D. ZHAO¹, B.-X. ZHANG², X.-H. CUI², J. ZHANG², N. DU², Y. ZHANG²

¹Department of Oncosurgery, Weinan Central Hospital of Shanxi Province, Weinan, China

²Department of Thoracic Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Weidong Zhao and Boxiang Zhang contributed equally to this work

Abstract. – **OBJECTIVE:** Some researches have showed that long noncoding RNAs (lncRNAs) take part in varieties of biological behaviors during the tumor progression. This study aims to determine whether lncRNA AB073614 functioned in the metastasis of non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS: Real Time Quantitative Polymerase Chain Reaction (RT-PCR) was used to detect AB073614 expression in NSCLC tissues. Besides, wound healing assay and transwell assay were conducted in NSCLC cells. Furthermore, the mechanism assays were performed to identify how AB073614 functioned in the metastasis of NSCLC cells.

RESULTS: By comparing the expression level in adjacent tissues, AB073614 expression level in NSCLC samples was higher. Moreover, after AB073614 was knocked down, invasion and migration of NSCLC cells were inhibited. After AB073614 was over-expressed, invasion and migration of NSCLC cells were promoted. mRNA and protein expression level of CDKN1A was upregulated via knockdown of AB073614, while mRNA and protein expression level of CDKN1A was down-regulated via over-expression of AB073614. Besides, the expression of CDKN1A in NSCLC tissues was negatively correlated to the expression of AB073614.

CONCLUSIONS: Our results indicated that AB073614 could enhance cell migration and cell invasion in NSCLC through repressing CDKN1A, which might offer a potential therapeutic choice for NSCLC.

Keywords:

noncoding RNA, AB073614, NSCLC, CDKN1A.

Introduction

Lung cancer, which is one of the top causes of tumor-related death globally, stills remain a huge threat to the public¹. As the major subgroup of cancer, non-small cell lung cancer (NSCLC) accounts for almost 85% of all lung cancer cases². Though tremendous advances have been made to reduce the mortality of lung cancer, the prognosis of patients with lung cancer is far from satisfaction, and the 5-year survival rate of the cases remains only 16%³. The main management for NSCLC patients at an early stage is surgical resection combined with chemotherapy. Unfortunately, most of the patients eventually develop disease progression and require further intervention⁴. Metastasis is the leading cause of the high mortality in NSCLC. Thus, it's important to understand the molecular basis underlying the metastasis of NSCLC and improve the poor prognosis of patients with NSCLC.

Advances in human genome sequencing have revealed that non-coding RNAs (ncRNAs) account for almost 99% of total transcribed RNAs. Long noncoding RNAs (lncRNAs), defined as transcription longer than 200 nucleotides, is an important group of ncRNAs. LncRNAs have been indicated to be key regulators in numerous processes, including the development of diverse cancers. For example, by modulating SF1 and suppressing expression level of miR-184, lncRNA UCA1 accelerates cell proliferation and cisplatin resistance in oral squamous cell carcinoma⁵. Through targeting miR-221/SOCS3, lncRNA GAS5 suppresses cell proliferation, cell metastasis, and gemcitabine resistance in pancreatic

cancer⁶. lncRNA RUNX1-IT1 act as an anti-oncogene in colorectal cancer by the inhibition of cell proliferation and cell migration which could function as a novel diagnostic biomarker⁷. Moreover, lncRNA ATB promotes cell migration and cell invasion in glioma by activating astrocytes through suppressing the expression of microRNA 2043p⁸. lncRNA AB073614 has recently been identified as a novel lncRNA in cancer tissues and cells. We aimed to determine whether LINP1 participates in the metastasis of NSCLC and the potential mechanism.

Patients and Methods

Patients and Sample Collection

In this research, 60 NSCLC patients were randomly selected and received surgery at Weinan Central Hospital of Shannxi Province. This study was approved by the Ethics Committee of Weinan Central Hospital of Shannxi Province. The signed written informed consents were obtained from all participants before the investigation.

Cell Culture and Cell Transfection

SPCA1, PC-9, H1975, and normal human bronchial epithelial cell16HBE (Shanghai Model Cell Bank; Shanghai, China) were cultured in penicillin, Roswell Park Memorial Institute-1640 (RPMI-1640; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA).

RNA Extraction and Real-time-Quantitative Polymerase Chain Reaction (RT-qPCR)

Total RNA was extracted from collected frozen tissue samples and cell lines with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and was reverse-transcribed into complementary deoxyribose nucleic acids (cDNAs) through reverse transcription Kit (Takara Biotechnology Co., Ltd., Dalian, China). mRNA levels were quantified by SYBR Green I. The PCR products were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using the following primers: AB073614, forward: 5'-ATCTGCTCTGGGTCTTAC-3' and reverse: 5'-CTGGCTTGTCTGTAGAGTC-3'; GAPDH, forward: 5'-CCAAAATCAGATGGCAATGCTGG-3' and reverse: 5'-TGATGGGAGACTGTGGTCATTCA-3'. RT-qPCR was performed by the ABI 7500 system (Applied Biosystems, Foster City, CA, USA).

Cell Transfection

Lentivirus expressing short-hairpin RNA (shRNA) and lentivirus against LINP1 was provided by GenePharma (Shanghai, China). AB073614 shRNA (sh-AB073614) and the empty vector (control) were then used for the transfection in SPCA1 and PC-9 cells using polybrene (GenePharma, Shanghai, China) when the density of cells reached 70%. AB073614 lentivirus (sh-AB073614) and the empty vector (control) were then used for transfection in PC-9 cells using polybrene (GenePharma, Shanghai, China) when the density of cells reached 70%.

Western Blot Analysis

To investigate the relative protein expression, treated cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed using lysis buffer. Reagent for immunoprecipitation assay (RIPA) was utilized to extract the protein from cells. Bicinchoninic acid (BCA) protein assay kit (Pierce and Warriner, China) was chosen for quantifying protein concentrations. The target proteins were separated by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). 5% fat-free milk was used to block non-specific protein interactions in Tris-Buffered Saline and Tween (TBST) which contains Tris-HCl (50 mM), NaCl (150 mM), and Tween 20 (0.05%) at 4°C for 1h. Then, they were incubated with antibodies after replaced to the polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). Abcam (Abcam, Cambridge, MA, USA) provided us with rabbit anti-GAPDH and rabbit anti-CDKN1A, as well as goat anti-rabbit secondary antibody. Enhanced chemiluminescence (ECL; Millipore, Billerica, MA, USA) was applied for the assessment of protein expression.

Wound Healing Assay

Empty vector, AB073614 shRNA or AB073614 lentivirus were transfected into NSCLC cells. These treated cells were cultured in 6-well plates and grew to about 90% confluent. Then, they were scratched by a sterile 10 µL pipette tip across the confluent cell layer and incubated in serum-free medium at 37°C in a humidified incubator containing 5% CO₂ for 24 h. Wound closure was captured using a light microscope (DFC500, Munich, Germany).

Transwell Assay

5×10^4 cells in 200 μ L serum-free RPMI-1640 were transformed to top chamber of an 8 μ m pore size insert (Corning, Corning, NY, USA) coated with or without 50 μ g Matrigel (BD, Bedford, MA, USA). Serum-free medium was added into the upper chamber, and 10% FBS medium supplemented was then added into the lower chamber. After 48 h, the top surface of chambers was immersed for 10 min with by 100% precooled methanol after wiped by cotton swab. Then, they were stained in crystal violet for 30 min and inspected with the microscope (Olympus, Tokyo, Japan). Five fields were used to count the data for migration and invasion membrane.

Statistical Analysis

Statistical analysis was conducted by Statistical Product and Service Solutions (SPSS) 19.0 software (IBM, Armonk, NY, USA). Statistical data was presented with GraphPad Prism software (La Jolla, CA, USA). Data were presented as mean $\pm$ SD (Standard Deviation). An independent-sample test was used to compare continuous data. The relative expression of mRNA was measured using the method of $2^{-\Delta\Delta CT}$. Results were considered statistically significant at $p < 0.05$.

Results

Expression Level of AB073614 Was Significantly Elevated in NSCLC Samples and Cell Lines

Firstly, the expression level of AB073614 was detected by performing RT-qPCR in 60 NSCLC

patients' samples and 3 NSCLC cell lines. The result revealed that AB073614 was significantly upregulated in tumor tissue samples (Figure 1A). AB073614 expression in NSCLC cells was remarkably higher when compared with that in 16HBE cell line (Figure 1B).

Knockdown of AB073614 Inhibited NSCLC Cell Migration

SPCA1 NSCLC cell line was used for the knockdown of AB073614. The AB073614 expression was detected by RT-qPCR (Figure 2A). To evaluate the biological role of AB073614 in NSCLC cell migration, we investigated AB073614 on NSCLC cell migration. As shown in wound healing assay, the knockdown of AB073614 inhibited SPCA1 cell migration compared with the negative control (Figure 2B). Meanwhile, the effects of knockdown of AB073614 on SPCA1 cell migration measured by the transwell assay were the same. The results revealed that after AB073614 was knocked down, the number of migrated SPCA1 NSCLC cells was decreased (Figure 3A).

Overexpression of AB073614 Promoted NSCLC Cell Migration

PC-9 NSCLC cell line was used for the overexpression of AB073614. The AB073614 expression was detected by RT-qPCR (Figure 2C). To evaluate the biological role of AB073614 in NSCLC cell migration, we investigated AB073614 on NSCLC cell migration. As shown in wound healing assay, the overexpression of AB073614 promoted the PC-9 cell migration compared with the neg-




Figure 1. Expression levels of AB073614 were increased in NSCLC tissues and cell lines. **A**, AB073614 expression was significantly increased in the NSCLC tissues compared with adjacent tissues. **B**, Expression levels of AB073614 relative to GAPDH were determined in the human NSCLC cell lines and normal human bronchial epithelial cell (16HBE) by RT-qPCR. Data are presented as the mean $\pm$ standard error of the mean. * $p < 0.05$.




Figure 2. Wound healing assay showed that AB073614 promoted NSCLC cell migration. **A**, AB073614 expression in SPCA1 NSCLC cells transduced with AB073614 shRNA (sh-AB073614) and the empty vector (control) was detected by RT-qPCR. GAPDH was used as an internal control. **B**, Wound healing assay showed that migrated length of SPCA1 NSCLC cells was significantly decreased via knockdown of AB073614. **C**, AB073614 expression in PC-9 NSCLC cells transduced with AB073614 lentivirus (AB073614) and the empty vector (control) was detected by RT-qPCR. GAPDH was used as an internal control. **D**, Wound healing assay showed that migrated length of PC-9 NSCLC cells was significantly increased via overexpression of AB073614. The results represent the mean $\pm$ standard error of the mean. * $p < 0.05$. ** $p < 0.01$.

ative control group (Figure 2B). While, the effects of the overexpression of AB073614 on PC-9 cell migration measured by the transwell assay were the same. The results showed that after AB073614 was overexpressed, the number of migrated PC-9 NSCLC cells was increased (Figure 3B).

AB073614 Promotes NSCLC Cell Invasion

We next evaluated the action of AB073614 in NSCLC cell invasion. As shown in the transwell assay, after AB073614 was knocked down, the cell invaded ability in SPCA1 NSCLC cells was repressed (Figure 3C). Besides, after AB073614 was overexpressed, cell invaded ability in PC-9 NSCLC cells was promoted (Figure 3D).

AB073614 Overexpressed CDKN1A Expression Directly

Previous studies showed that CDKN1A was overexpressed and regulated in many tumors including NSCLC, and it was found to be regulated by many lncRNAs and mediated the function of lncRNAs

in many malignant tumors. Then, to further verify the actual relationship between CDKN1A and AB073614, we further detected the CDKN1A expression of SPCA1 cells transfected with AB073614 shRNA (sh-AB073614) or the empty vector (control). The results of RT-qPCR showed that the expression level of CDKN1A was significantly higher in AB073614 shRNA (sh-AB073614) group in SPCA1 NSCLC cells compared with that in empty vector (control) group (Figure 4A). And the expression level of CDKN1A was significantly lower in AB073614 lentivirus (AB073614) group in PC-9 NSCLC cells compared with that in empty vector (control) group (Figure 4B). Besides, the results of Western blot assay revealed that expression level of CDKN1A was significantly higher in AB073614 shRNA (sh-AB073614) group in NSCLC cells compared with that in empty vector (control) group (Figure 4C). And the expression level of CDKN1A was significantly lower in AB073614 lentivirus (AB073614) group in NSCLC cells compared with that in empty vector (control) group (Figure 4D). Furthermore, we found out




Fig. 4. Transwell assay showed that AB073614 promoted NSCLC cell migration and invasion. **A**, Transwell assay showed that number of migrated cells was significantly decreased *via* knockdown of AB073614 in SPCA1 NSCLC cells (magnification, 40X). **B**, Transwell assay showed that number of migrated cells was significantly increased *via* overexpression of AB073614 in SPCA1 NSCLC cells (magnification, 40X). **C**, Transwell assay showed that number of invaded cells was significantly decreased *via* knockdown of AB073614 in SPCA1 NSCLC cells (magnification, 40X). **D**, Transwell assay showed that number of invaded cells was significantly increased *via* overexpression of AB073614 in PC-9 NSCLC cells (magnification, 40X). The results represent the average of three independent experiments.




Figure 3. AB073614 suppressed CDKN1A expression directly in NSCLC cells and tissues. **A**, RT-qPCR results showed that CDKN1A expression was higher in AB073614 shRNA (sh-AB073614) compared with the empty vector (control). **B**, RT-qPCR results showed that CDKN1A expression was lower in AB073614 lentivirus (AB073614) compared with the empty vector (control). **C**, Western blot results showed that CDKN1A expression was upregulated in AB073614 shRNA (sh-AB073614) compared with the empty vector (control). **D**, Western blot results showed that CDKN1A expression was downregulated in AB073614 lentivirus (AB073614) compared with the empty vector (control). **E**, CDKN1A was significantly downregulated in NSCLC tissues compared with adjacent tissues. **F**, The linear correlation between the expression level of CDKN1A and AB073614 in NSCLC tissues. The results represent the average of three independent experiments. Data are presented as the mean $\pm$ standard error of the mean. * $p < 0.05$.

the expression of CDKN1A in NSCLC tissues was significantly lower when compared with that of adjacent tissues (Figure 4E). Correlation

analysis demonstrated that CDKN1A expression level negatively correlated to AB073614 expression in NSCLC tissues (Figure 4F).

Discussion

Lung cancer (LC) ranks the second common cancer among human malignant tumors. 80% of lung cancer is NSCLC worldwide⁹. The incidence of NSCLC in China accounts for more than half of the whole world¹⁰. Although molecular targeted therapy is available for NSCLC patients, only a small part of patients benefits from those discovered driver mutations. Therefore, it is urgent to find more potential regulators and targets for treatment of NSCLC.

It has been reported in numerous researches that non-coding RNAs (ncRNAs) take part in varieties of biological behaviors during the tumor progression. Known as subgroups of ncRNAs family, long noncoding RNAs (lncRNAs) are non-coding RNA molecules which are longer than 200 bp and cannot be transcribed into protein. Moreover, it was found that lncRNAs are related to various kinds of cellular functions including carcinogenesis and metastasis.

In recent years, increasing studies have demonstrated that lncRNAs serve as important regulators in lung cancer initiation and progression. For example, through regulating PI3K/AKT-488-HEY2 signal network, lncRNA PRN1 functions as an oncogene in NSCLC and promotes tumor progression¹¹. The overexpression of lncRNA-p21 suppresses cell growth in NSCLC by directly decreasing expression level of PUMA¹².

LncRNA AB073614 is a newly discovered lncRNA in a few malignant tumors including NSCLC. It has been reported to participate in tumor development and metastasis. For instance, AB073614 promotes tumorigenesis in ovarian cancer which is closely related to the poor prognosis of patients with ovarian cancer¹³. By modulating the PI3K/AKT signaling pathway, AB073614 plays an important role in the regulation of proliferation and cell migration in colorectal cancer. Through regulating epithelial-mesenchymal transition, AB073614 promotes tumor proliferation and cell migration in glioma which indicates a poor prognosis in cases with glioma¹⁴. To date, there has not been any study on the correlation between lncRNA AB073614 and NSCLC tumorigenesis. In this research, we figured out that the AB073614 is remarkably higher-expressed in NSCLC samples. Besides, after AB073614 was knocked down, cell migration and cell invasion in NS-

CLC cell were inhibited. And after AB073614 was overexpressed, cell migration and cell invasion in NSCLC cell were promoted. These results indicated that AB073614 might act as an oncogene in NSCLC.

To further identify the underlying mechanism of how AB073614 affects NSCLC tumorigenesis and metastasis, we predicted and selected CDKN1A as the potential binding protein of AB073614 by using bioinformatics analysis and experimental verification. Some studies have reported that CDKN1A acts as anti-metastatic and anti-tumor roles in variety of cancers. Cyclin-dependent kinase inhibitor, especially CDKN1A, is a canonical Myc target gene and tumor suppressor¹⁵. For example, by suppressing CDKN1A, a positive feedback loop, EZH2 controls the proliferation of germinal center B cell and enables cell cycle progression¹⁷. CDKN1A inhibits cell proliferation in breast tumor by regulating CDKN1A transcription expression which may provide an attractive targeted therapeutic. CDKN1A could enhance the response of cutaneous melanoma to radiotherapy by manipulating Langerhans cell survival and promoting Treg cell generation¹⁹. In addition, CDKN1A gene is closely correlated with prognosis of patients with gastric adenocarcinoma resection²⁰. In our research, CDKN1A expression could be upregulated after knockdown of AB073614, while CDKN1A expression could be downregulated after overexpression of AB073614. Moreover, CDKN1A expression in NSCLC samples was negatively related to AB073614 expression. All the results above suggested that AB073614 might promote tumorigenesis of NSCLC via downregulating CDKN1A.

Conclusions

We showed that AB073614 was remarkably upregulated in patients with NSCLC. Besides, AB073614 could enhance migration and invasion of NSCLC cells through repressing CDKN1A. These findings suggest that AB073614 may contribute to therapy for NSCLC as a candidate target.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) SIEGEL R, MA J, ZOU Z, JEMAL A. Cancer statistics, 2014. *CA Cancer J Clin* 2014; 64: 9-29.
- 2) ZHENG HE, WANG G, SONG J, LIU Y, LI YM, DU WP. MicroRNA-495 inhibits the progression of non-small-cell lung cancer by targeting TCF4 and inactivating Wnt/beta-catenin pathway. *Eur Rev Med Pharmacol Sci* 2018; 22: 7750-7759.
- 3) LIU Z, JIANG L, ZHANG G, LI S, JIANG X. MiR-24 promotes migration and invasion of non-small cell lung cancer by targeting ZNF367. *J BUON* 2018; 23: 1413-1419.
- 4) YUSEN W, XIA W, SHENGJUN Y, SHAOHUI Z, HONGZHEN Z. The expression and significance of tumor associated macrophages and CXCR4 in non-small cell lung cancer. *J BUON* 2018; 23: 398-402.
- 5) FANG Z, ZHAO J, XIE W, SUN Q, WANG H, QIAO B. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. *Cancer Med* 2017; 6: 2897-2908.
- 6) LIU B, WU S, MA J, YAN S, XIAO Z, WAN L, ZHANG F, SHANG M, MAO A. lncRNA GAS5 reverses EMT and tumor stem cell-mediated gemcitabine resistance and metastasis by targeting miR-221/SOCS3 in pancreatic cancer. *Mol Ther Nucleic Acids* 2018; 13: 472-482.
- 7) SHI J, ZHONG X, SONG Y, WU Z, GAO P, ZHANG J, WANG J, LIU J, WANG Z. Long non-coding RNA RUNX1-IT1 plays a tumour-suppressive role in colorectal cancer by inhibiting cell proliferation and migration. *Cell Biochem Funct* 2019; 37: 1-20.
- 8) BIAN EB, CHEN EF, XU YD, YANG JF, MA CC, WANG HL, ZHAO B. Exosome-miR-141-3p activates astrocytes that promote glioma cell invasion. *Int J Oncol* 2019; 54: 713-721.
- 9) RIZOU T, PERLIKOS F, MAGIOLAKI E, KALINI MI, KALIOPOULOS S, TOUMPOURIS A, KRIOSTOTIDOU A. Development of novel real-time RT-qPCR methodologies for quantification of the COL11A1 gene in general and C transgenic evaluation in non-small cell lung cancer specimens. *J BUON* 2018; 23: 1699-1710.
- 10) CHEN Y, ELLMORE CM, HAMMILL JS, KIM CF, WONG KK. Non-small-cell lung cancers: a heterogeneous set of diseases. *Nat Rev Cancer* 2014; 14: 545-556.
- 11) CHENG D, BAO C, ZHANG X, LIN X, HUANG H, ZHAO L. LncRNA PRNCR1 interacts with HEY2 to abolish miR-448-mediated growth inhibition in non-small cell lung cancer. *Biomed Pharmacother* 2018; 107: 1540-1547.
- 12) YANG T, ZHANG W, WANG L, XIAO Y, GUO B, GONG Y, LIANG X, HUANG D, LI Q, NAI Y, SHAO J. Long intergenic noncoding RNA linc-0001 inhibits apoptosis by decreasing pUMA expression in non-small cell lung cancer. *J Int Med* 2018; 263: 1218616144.
- 13) CHENG Z, GUO J, CHEN Z, LUO M, ZHANG W, QU X. A long noncoding RNA AB073614 promotes tumorigenesis and indicates poor prognosis in ovarian cancer. *Oncotarget* 2017; 8: 5381-5393.
- 14) WANG Y, LIU H, XUE J, LIANG Y, CHOU X. LncRNA linc-0001 regulates proliferation and metastasis of cervical cancer cells via the PI3K/AKT signaling pathway. *Biomed Pharmacother* 2017; 93: 1230-1235.
- 15) ZHANG YM, SONG YE. Knockdown of long non-coding RNA AB073614 inhibits glioma cell proliferation and migration via affecting epithelial-mesenchymal transition. *Eur Rev Med Pharmacol Sci* 2016; 20: 399-402.
- 16) TCHOUCHUTINA I, KERNOVICH R, GENG H, JOHNSON NA, MELNICK AM, ELEMENTO O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. *Blood* 2010; 116: 5247-5255.
- 17) CHEN W, RIVAS MA, CALVO FM, TEATER M, PURWADA A, EDMOND D, SHEN H, CHALLMAN MF, ELEMENTO O, SINGH A, MELNICK AM. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. *Nat Commun* 2017; 8: 877.
- 18) BIANCO S, JANGAL M, GARNEAU D, GEVRY N. LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression. *Oncogene* 2015; 34: 4509-4518.
- 19) PRICE JG, IDOYAGA J, SALMON H, HOGSTAD B, BIGARELLA CL, GHAFFARI S, LEBOEUF M, MERAD M. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. *Nat Immunol* 2015; 16: 1060-1068.
- 20) NIE X, WANG X, LIN Y, YU Y, LIU W, XIE F, WANG X, TAN J, HUANG Q. SNP rs1059234 in CDKN1A gene correlates with prognosis in resected gastric adenocarcinoma. *Clin Lab* 2016; 62: 409-416.